semaglutide egfr cut off of semaglutide - TirzepatideeGFR cut off eGFR Understanding the Semaglutide eGFR Cut-Off: A Comprehensive Guide

eGFRcalculator The intersection of diabetes, obesity, and chronic kidney disease (CKD) presents a complex challenge in modern medicine. As treatments evolve, understanding the specific parameters for their effective and safe use becomes paramount. One such area of focus is the eGFR cut-off for semaglutide, a GLP-1 receptor agonist increasingly recognized for its multifaceted benefits, including its impact on kidney health.Long-term kidney outcomes of semaglutide in obesity and ... This article delves into the nuances of semaglutide's use concerning estimated glomerular filtration rate (eGFR), exploring its efficacy, safety, and the latest research findings作者：EM Apperloo·2025·被引用次数：16—In the SUSTAIN 6 trial,eGFRslope was –1.32 mL/min/1.73 m2in thesemaglutidegroup compared with –1.92 mL/min/1.73 m2in the placebo group [ ....

What is eGFR and Why is it Crucial for Semaglutide Use?

eGFR, or estimated glomerular filtration rate, is a key indicator of kidney function.Effect of semaglutide on kidney function across different levels ... It measures how well your kidneys are filtering waste products from your blood. The units of eGFR are typically expressed as milliliters per minute per 1.73 square meters of body surface area (mL/min/1.73 m²)FDA expanded subcutsemaglutideOZEMPIC indication to ↓ the riskofsustainedeGFRdecline, ESKD, and CV death in adults with T2DM & CKD January 2025.FDA.. Lower eGFR values signify declining kidney function, a condition that can progress to kidney failure if left unmanaged.

For medications like semaglutide, kidney function is a critical considerationEffects of Semaglutide on Chronic Kidney Disease in T2DM. The way a drug is metabolized and excreted can be significantly altered by compromised kidney function. Therefore, establishing an eGFR of cut-off is essential to ensure patient safety and optimize therapeutic outcomesFDA expanded subcutsemaglutideOZEMPIC indication to ↓ the riskofsustainedeGFRdecline, ESKD, and CV death in adults with T2DM & CKD January 2025.FDA..

Semaglutide and Kidney Protection: Evidence and Insights

Recent research and clinical trials have highlighted the significant role of semaglutide in preserving kidney function, particularly in individuals with type 2 diabetes (T2DM) and chronic kidney disease (CKD).eGFR Cut-Off for Glucose Lowering Therapies The FLOW trial and the SUSTAIN 6 trial are pivotal studies in this regard.

The SUSTAIN 6 trial, for example, demonstrated that in a subset of patients with baseline eGFR <60 mL/min/1.73 m², semaglutide showed an even greater effect on slowing kidney function decline. The eGFR slope in the semaglutide group was –1.32 mL/min/1.73 m2 compared to –1.92 mL/min/1.73 m2 in the placebo group. This suggests a protective effect, potentially by reducing intraglomerular pressure and inflammation.GLP-1 receptor agonists in diabetic kidney disease - PMC - NIH

Furthermore, findings from the FLOW trial, published in *Nature Medicine*, indicated that semaglutide consistently reduces eGFR decline. At 104 weeks, the benefit for eGFR was 0.75 mL/min/1.Long-term kidney outcomes of semaglutide in obesity and ...73m² (95% CI 0作者：EM Apperloo·2025·被引用次数：16—In the SUSTAIN 6 trial,eGFRslope was –1.32 mL/min/1.73 m2in thesemaglutidegroup compared with –1.92 mL/min/1.73 m2in the placebo group [ ....43-1.06; P < 0.001) in favor of semaglutide when compared to placebo, in patients with baseline eGFR ≥60 ml/min−1/1.73 m⁻². This consistent reduction in eGFR decline translates to a tangible benefit in preserving kidney health over the long term作者：JJ Long·2024·被引用次数：12—We included adult patients (>18 year old) witheGFR15-29 mL/min/1.73 m2(CKD stage 4) andeGFR<15 mL/min/1.73 m2(CKD stage 5) or on dialysis (CKD stage 5D) ....

Understanding the Specific eGFR Cut-Offs for Semaglutide

The specific eGFR cut-off for initiating semaglutide therapy can vary slightly depending on the formulation and the prescribing guidelines. However, a general consensus has emerged from the available data and drug information.

For oral semaglutide (Rybelsus), current guidance suggests that it should not be initiated if the eGFR is less than 15 ml/min. This means that patients with CKD stage 5 or those on dialysis (CKD stage 5D) may not be candidates for initiation of this particular formulation.

For subcutaneous semaglutide (Ozempic, Wegovy), the FDA expanded its indication in January 2025 to reduce the risk of sustained eGFR decline, end-stage kidney disease (ESKD), and cardiovascular death in adults with T2DM and CKD.eGFR Cut-Off for Glucose Lowering Therapies While the expanded indication underscores the renal benefits, it's always crucial to consult the latest prescribing information for precise initiation criteria for patients with severely impaired kidney function. Studies have included adult patients with eGFR 15-29 mL/min/1.Study revealssemaglutide's potential in lowering elevated urine albumin levelsin overweight chronic kidney disease patients. Semaglutide ...73 m² (CKD stage 4) and eGFR <15 mL/min/1.73 m² (CKD stage 5) or on dialysis.Impact of Oral Semaglutide on Kidney Outcomes in People With Type 2 ...

Beyond eGFR: Semaglutide's Broader Impact on Kidney Health

The benefits of semaglutide for kidney health extend beyond merely slowing eGFR decline. Emerging evidence points to semaglutide's potential in lowering elevated urine albumin levels in overweight patients with chronic kidney diseaseeGFR Cut-Off for Glucose Lowering Therapies. Albuminuria, the presence of albumin in the urine, is a significant marker of kidney damage and a predictor of CKD progressionSemaglutide. Consult current SmPC prior to prescribing. Last Updated 11/01/2025. Rybelsus – oralSemaglutide. Do not initiate ifeGFR<. 15ml/min.. By reducing albuminuria, semaglutide may offer a dual benefit: preserving GFR and mitigating other markers of kidney injury2024年6月11日—The treatment benefit at 104 weeks foreGFRwas 0.75 ml/min/1.73m2 (95% CI 0.43-1.06; P < 0.001) in favorof semaglutide(Colhoun et al, Nat Med ....

Furthermore, in patients with T2DM and CKD, semaglutide has shown promise in reducing the risk of major kidney disease events, a composite outcome that includes the onset of kidney failure necessitating dialysis or transplantation.

Expert Considerations and Future Directions

Healthcare professionals carefully consider multiple factors when prescribing semaglutide, including the patient's baseline eGFR, the presence of comorbidities such as T2DM and obesity, and the individual's risk profile for cardiovascular and kidney events. While semaglutide demonstrates significant renal protective effects, it's not a cure for kidney disease.

The ongoing research into semaglutide's long-term effects on kidney outcomes, as seen in studies like the FLOW trial, continues to refine our understanding of its place in managing patients with kidney compromise2024年6月11日—The treatment benefit at 104 weeks foreGFRwas 0.75 ml/min/1.73m2 (95% CI 0.43-1.06; P < 0.001) in favorof semaglutide(Colhoun et al, Nat Med .... The exploration of semaglutide vs Tirzepatide in terms of renal outcomes is also an area of active investigation, as both are powerful medications with the potential to impact kidney health.

In conclusion, the semaglutide eGFR cut-off is a critical parameter that guides its safe and effective use. While generally not recommended for initiation in those with an eGFR below 15 ml/min for oral formulations, the drug's demonstrated capacity to protect and even improve kidney function in broader patient populations with CKD is a significant therapeutic advancement. Continuous monitoring of renal parameters and adherence to updated clinical guidelines are essential for optimizing the benefits of semaglutide in preserving kidney health.